Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Novel Splicing Variant in the PMM2 Gene in a Patient With PMM2-CDG Syndrome Presenting With Pericardial Effusion: A Case Report

K. Slaba, H. Noskova, P. Vesela, J. Tuckova, H. Jicinska, T. Honzik, H. Hansikova, P. Kleiblova, P. Stourac, P. Jabandziev, O. Slaby, D. Prochazkova,

. 2020 ; 11 (-) : 561054. [pub] 20201007

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21002001

Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases with the phosphomannomutase 2 (PMM2)-CDG being the most common form of CDG. Most of these monogenic diseases are autosomal recessive and have multi-systemic manifestations, mainly psychomotor retardation, facial dysmorphisms, characteristic distribution of the fat pads, and variable coagulation abnormalities. The association of fetal hydrops with CDG has been reported, and pericardial effusion was also rarely observed in patients with PMM2-CDG. Here we describe an infant boy with PMM2-CDG. The diagnosis was suspected based on inverted nipples, fat pads, and combined coagulopathy. However, the primary symptom was progressive pericardial effusion leading to patient death at the age of 3 months. Screening for CDG performed by the use of isoelectric focusing of serum transferrin showed a typical PMM2-CDG pattern. Exome sequencing revealed one common pathogenic variant (c.691G > A/p.Val231Met) and one novel variant (c.447 + 3dupA) in the PMM2 gene. Both PMM2 variants were further confirmed by Sanger sequencing in both the proband and the parents' DNA. The novel variant was predicted to result in loss of donor splice site, and the analysis at mRNA level confirmed that it leads to exon five skipping (r.348_447del) and causes premature termination of translation to the protein (p.G117Kfs∗4), therefore is classified as likely pathogenic. Although there is no curative therapy for the PMM2-CDG at the moment, the other supportive care options are available to be offered. The definite diagnosis of PMM2-CDG can also assist in the process of genetic counseling, family planning, and preimplantation genetic diagnosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21002001
003      
CZ-PrNML
005      
20210126092710.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fgene.2020.561054 $2 doi
035    __
$a (PubMed)33133147
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Slaba, Katerina $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
245    10
$a Novel Splicing Variant in the PMM2 Gene in a Patient With PMM2-CDG Syndrome Presenting With Pericardial Effusion: A Case Report. / $c K. Slaba, H. Noskova, P. Vesela, J. Tuckova, H. Jicinska, T. Honzik, H. Hansikova, P. Kleiblova, P. Stourac, P. Jabandziev, O. Slaby, D. Prochazkova,
520    9_
$a Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases with the phosphomannomutase 2 (PMM2)-CDG being the most common form of CDG. Most of these monogenic diseases are autosomal recessive and have multi-systemic manifestations, mainly psychomotor retardation, facial dysmorphisms, characteristic distribution of the fat pads, and variable coagulation abnormalities. The association of fetal hydrops with CDG has been reported, and pericardial effusion was also rarely observed in patients with PMM2-CDG. Here we describe an infant boy with PMM2-CDG. The diagnosis was suspected based on inverted nipples, fat pads, and combined coagulopathy. However, the primary symptom was progressive pericardial effusion leading to patient death at the age of 3 months. Screening for CDG performed by the use of isoelectric focusing of serum transferrin showed a typical PMM2-CDG pattern. Exome sequencing revealed one common pathogenic variant (c.691G > A/p.Val231Met) and one novel variant (c.447 + 3dupA) in the PMM2 gene. Both PMM2 variants were further confirmed by Sanger sequencing in both the proband and the parents' DNA. The novel variant was predicted to result in loss of donor splice site, and the analysis at mRNA level confirmed that it leads to exon five skipping (r.348_447del) and causes premature termination of translation to the protein (p.G117Kfs∗4), therefore is classified as likely pathogenic. Although there is no curative therapy for the PMM2-CDG at the moment, the other supportive care options are available to be offered. The definite diagnosis of PMM2-CDG can also assist in the process of genetic counseling, family planning, and preimplantation genetic diagnosis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Noskova, Hana $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
700    1_
$a Vesela, Petra $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
700    1_
$a Tuckova, Jana $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
700    1_
$a Jicinska, Hana $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
700    1_
$a Honzik, Tomas $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
700    1_
$a Hansikova, Hana $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
700    1_
$a Kleiblova, Petra $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
700    1_
$a Stourac, Petr $u Department of Pediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
700    1_
$a Jabandziev, Petr $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia. Central European Institute of Technology, Masaryk University, Brno, Czechia.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czechia. Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia.
700    1_
$a Prochazkova, Dagmar $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia. Institute of Medical Genetics, Faculty of Medicine, Masaryk University, Brno, Czechia.
773    0_
$w MED00184539 $t Frontiers in genetics $x 1664-8021 $g Roč. 11, č. - (2020), s. 561054
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33133147 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092706 $b ABA008
999    __
$a ind $b bmc $g 1614107 $s 1122285
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 561054 $e 20201007 $i 1664-8021 $m Frontiers in genetics $n Front Genet $x MED00184539
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...